Please login to the form below

Not currently logged in
Email:
Password:

Tresiba

This page shows the latest Tresiba news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk fends off Lilly’s GLP-1 challenge in Q1

Novo Nordisk fends off Lilly’s GLP-1 challenge in Q1

This was despite growth for new long-acting insulin Tresiba (insulin degludec), which grew 33% to DKK 1.75bn in local currencies.

Latest news

More from news
Approximately 31 fully matching, plus 43 partially matching documents found.

Latest Intelligence

  • Harnessing commercial innovation Harnessing commercial innovation

    products - such as basal insulin Tresiba and its Ryzodeg and Xultophy combinations. “

  • Interview: Peter Meeus, Novo Nordisk Interview: Peter Meeus, Novo Nordisk

    Not reporting it is a very big issue.”. Novo has attempted to address hypoglycaemia with the launch of its new insulin Tresiba (insulin degludec), which was approved in Europe at the ... Tresiba has also demonstrated it is just as effective even when

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

We are industry-leading thinkers when it comes to education. We use the latest academic thinking on the psychology of behaviour...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics